Перейти к содержанию

Alkermes plc. (ALKS) stock: revenue, earnings & dividend

Alkermes plc. (ALKS, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ALKS · Nasdaq Pharma & Biotech IE-

Key figures

Fiscal year
2025
Revenue
1.48 bn $
Revenue growth
-5.3 %
Revenue growth 5y (p.a.)
7.3 %
Net income
242 m $
Net margin
16.4 %
Operating margin
17.2 %
Earnings per share (diluted)
1.43 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
2.49 bn $
Equity
1.82 bn $
Equity ratio
73.2 %
Return on equity
13.3 %
Cash
389 m $
Operating cash flow
521 m $
Free cash flow
480 m $
Shares outstanding
168,043,540

History

Revenue by fiscal year

2016 746 m $
2017 903 m $
2018 1.09 bn $
2019 1.17 bn $
2020 1.04 bn $
2021 1.17 bn $
2022 1.11 bn $
2023 1.66 bn $
2024 1.56 bn $
2025 1.48 bn $

Net income by fiscal year

2016 -208.44 m $
2017 -157.95 m $
2018 -139.31 m $
2019 -196.62 m $
2020 -110.86 m $
2021 -48.2 m $
2022 -158.3 m $
2023 356 m $
2024 367 m $
2025 242 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.48 bn $242 m $1.43 $–521 m $
20241.56 bn $367 m $2.17 $–439 m $
20231.66 bn $356 m $2.10 $–401 m $
20221.11 bn $-158.3 m $-0.97 $–21 m $
20211.17 bn $-48.2 m $-0.29 $–102 m $
20201.04 bn $-110.86 m $-0.70 $–82.8 m $
20191.17 bn $-196.62 m $––72.1 m $
20181.09 bn $-139.31 m $––99.3 m $
2017903 m $-157.95 m $––19.2 m $
2016746 m $-208.44 m $––-63.8 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)